ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LFCR / forecast
IMRX (30) EVMN (31) IFRX (54) CAMP (26) ⌘ Pro Terminal →

Lifecore Biomedical Inc. (LFCR) 12-Month Stock Forecast & Price Target Cone

$6.40 -1.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.37

Lifecore Biomedical Inc. (LFCR) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $242.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LFCR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LFCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Lifecore Biomedical Inc. (NASDAQ: LFCR) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $6.40 (-1.84% 1D, market cap $242.3M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LFCR ranks #173 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LFCR compare to IMRX and EVMN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFCR carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IMRX (Immuneering Corporation (Class A)) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $242.5M) and EVMN (Evommune Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $244.2M). Among the 5-stock peer group, LFCR leads on earnings multiple (N/A) while IMRX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LFCR?
▼

Per LFCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001005286), Lifecore Biomedical Inc. generated $97.5M in revenue (-24.3% YoY), $0 in net income, and $0 in free cash flow against $232.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.37 (-0.52%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C-
025507510059
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Cash (11)Whales (14)SEC (13)Macro (12)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+0.5% Base Target
$9 Bull$6 Base$5 Bear
📬 FREE LFCR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFCR)Realized 20D OHLCV Swing Band: ±1.9%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY LFCR SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (24% of score)

20D Institutional Volume Accumulation (±1.9% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
67
Grade B-$6.42-0.8% Next Q
Q2 (-2Q)
64
Grade C+$6.37+1.1% Next Q
Q3 (-1Q)
62
Grade C+$6.44-0.6% Next Q
Current
59
Grade C-$6.40+0.2% Hist 90D α
Trajectory: B- (67) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LFCR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, LFCR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.50) or 200D SMA ($5.49) invalidates the momentum regime and cuts Target Base ($6.43) toward Bear Floor ($5.02).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LFCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LFCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 59%NO 41%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your LFCR Position Size: $10,000

Shares at $6.40: 1562.5 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $5.02
$7,844
$-2,156 (-21.6%)
12M Consensus BaseTarget $6.43
$10,047
+$47 (+0.5%)
12M Bull Case BreakoutTarget $9.43
$14,734
+$4,734 (+47.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$774%A
Goldman SachsSector Coverage LeadBUY$969%B
JP MorganUS Large-Cap ResearchHOLD$658%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LFCR Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LFCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.76%📐 HORIZONTAL RANGE
2026-11-03O $6.52H $6.52L $6.40C $6.40VOL 1.02M
RES: $7.34SUP: $3.89SMA50: $5.50SMA200: $5.49
$7.18$6.32$5.46$4.59$3.73RES $7.34SUP $3.89$6.402026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LFCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LFCR Butterfly Map → + Track LFCR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -24.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LFCR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LFCR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LFCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFCR)

Health Care Rank #173 of 1015 ⚔️ IMRX vs LFCR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LFCR vs. IMRX, EVMN, IFRX, CAMP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lifecore Biomedical Inc. (LFCR) ranks #173 by composite RQD confidence (59/100, grade C-) and #548 by equity capitalization ($242.3M). Within this direct 5-issuer industry benchmark cohort, LFCR leads on earnings valuation at N/A trailing P/E, while IMRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LFCR ACTIVE
Lifecore Biomedical Inc.
C- 59/100 — — — -1.84% $242.3M Benchmark Subject
IMRX
Immuneering Corporation (Class A)
E 30/100 — — -35.0% -6.84% $242.5M /imrx-vs-lfcr →
EVMN
Evommune Inc.
E 31/100 — — -35.0% -1.17% $244.2M /evmn-vs-lfcr →
IFRX
InflaRx N.V.
D+ 54/100 — — — -3.21% $244.6M /ifrx-vs-lfcr →
CAMP
CAMP4 Therapeutics Corporation
E 26/100 — — -35.0% +1.54% $248.5M /camp-vs-lfcr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001005286 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lifecore Biomedical Inc. (LFCR) reported GAAP revenue of $97.5M (-24.3% vs. FY2024 revenue of $128.9M , and +293.8% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LFCR closed FY2025 with $232.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $97.5M $0 — — $232.2M —
FY2024 (FY) 2024-05-25 $128.9M -$38.7M -$206.0K -$13.6M $255.4M $110.5M
FY2023 (FY) 2023-05-26 $24.8M $12.0M $257.0K $257.0K — —

3. LFCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LFCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Lifecore Biomedical Inc. (NASDAQ: LFCR) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $6.40 (-1.84% 1D, market cap $242.3M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LFCR ranks #173 in composite RQD confidence.

How does LFCR compare to IMRX and EVMN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFCR carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IMRX (Immuneering Corporation (Class A)) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $242.5M) and EVMN (Evommune Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $244.2M). Among the 5-stock peer group, LFCR leads on earnings multiple (N/A) while IMRX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LFCR?

Per LFCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001005286), Lifecore Biomedical Inc. generated $97.5M in revenue (-24.3% YoY), $0 in net income, and $0 in free cash flow against $232.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LFCR trading relative to its 50-day, 200-day, and 52-week technical levels?

LFCR last traded at $6.40 (-1.84% on volume of 1,023,945 shares), positioning the stock +16.36% above its 50-day simple moving average ($5.50) and +16.58% above its 200-day simple moving average ($5.49). Across its 52-week range of $3.63 to $8.98, LFCR sits at the 51.8% percentile with a 14-day RSI of 61.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.9% ($6.28 to $6.52).

Direct Sub-Reports: LFCR RQD Cockpit LFCR 12M Forecast LFCR Earnings & Move LFCR Dividends & DRIP LFCR Insiders & 13F LFCR Whale Options LFCR Profit Sankey LFCR News & Why
ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ SEC XBRL & RQD VERIFIED

LFCR — Lifecore Biomedical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lifecore Biomedical Inc. (LFCR) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $6.40 (-1.84% 1D, market capitalization $242.3M).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (LFCR) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. — for product lines, customers, or revenue model specifics beyond the sector and industry classification.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lifecore Biomedical Inc. (LFCR) reported $97.5M in annual revenue (up from $128.9M in FY2024, -24.3% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.8M revenue, $12.0M net income) through FY2025, LFCR scaled operating cash flow to $0 and free cash flow to $0, backed by $232.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C- • RQD 59/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 14/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $3.63 – $8.98 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are — Sector correlation data is — Second-order bottlenecks cannot be identified from the supplied sources.

  • Key Question #1: Can LFCR sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $97.5M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LFCR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LFCR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lifecore Biomedical Inc. (LFCR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LFCR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LFCR Bull vs. Bear Conversation Board — What's Your Call at $6.40?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LFCR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LFCR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $8.26 (+29.1%)
📌 Pinned Debate

The Forensic Balance Sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and the Whale 13F Flow pillar (13/20) indicat

The street is overcomplicating Lifecore Biomedical Inc. (LFCR). The Forensic Balance Sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and the Whale 13F Flow pillar (13/20) indicate financial survival metrics and some institutional interest are relatively stronger than the earnings base.. With an RQD score of 59/100 (C-) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $6.91.

SectorRotator 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $5.18 (-19.1%)
Spot @ $6.40

The Fundamental Cash Engine pillar scores 11/20 with ROIC at 0% and FCF yield at 0%, and FY 2024 shows a net loss of -$38.7M on $128.9M

Careful chasing LFCR at $6.40. The Fundamental Cash Engine pillar scores 11/20 with ROIC at 0% and FCF yield at 0%, and FY 2024 shows a net loss of -$38.7M on $128.9M revenue.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $5.18 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%